Pembrolizumab-Olaparib Boosts PFS in Non-BRCA Ovarian Cancer

(MedPage Today) — A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a randomized trial showed.
In…